STOCK TITAN

Clene Inc - CLNN STOCK NEWS

Welcome to our dedicated news page for Clene (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clene's position in the market.

Rhea-AI Summary
Clene Inc. has announced the pricing of an underwritten public offering of 50,000,000 shares of its common stock and two tranches of warrants. The combined offering price is $0.80 per share. Clene expects to receive total gross proceeds of approximately $40 million. The offering is expected to close on June 21, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.05%
Tags
offering
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.05%
Tags
offering
-
Rhea-AI Summary
Clene Inc. has reported new data showing a significant reduction in plasma neurofilament light chain (NfL) levels for participants treated with CNM-Au8 compared to placebo in the HEALEY ALS Platform Trial. NfL is a key biomarker of neurodegeneration and higher levels have been linked to more rapid decline in clinical function and increased mortality risk in ALS patients. The results support the potential of CNM-Au8 as a treatment for ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.05%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
earnings
Clene Inc

Nasdaq:CLNN

CLNN Rankings

CLNN Stock Data

54.63M
67.91M
40.13%
19.29%
0.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Salt Lake City

About CLNN

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.